Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

CSIR presents new antitumor agents

Oct. 19, 2011

Novel B-raf inhibitors disclosed by Boehringer Ingelheim

Oct. 19, 2011

Orantinib advances through studies in NSCLC and breast cancer

Oct. 19, 2011

Halozyme discloses clinical results on new Herceptin formulation

Oct. 19, 2011

Trial determines phase II doses of ixabepilone/cisplatin combination regimen in NSCLC

Oct. 19, 2011

Interim first-in-human data released on two c-Met inhibitors

Oct. 19, 2011

AB Science recruits first patient in phase III masitinib trial

Oct. 18, 2011

Infinity Pharmaceuticals provides update on IPI-926 trials

Oct. 18, 2011

Novel autotaxin inhibitors designed by Merck KGaA

Oct. 18, 2011

ABI-007 advances through trial in gastric cancer

Oct. 18, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...